Header Logo

Connection

CHARLES CLEELAND to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications CHARLES CLEELAND has written about Antibodies, Monoclonal.
CHARLES CLEELAND
Connection Strength
0.014
Antibodies, Monoclonal
  1. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 2016 Feb 12; 6:e396.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.